Applications of animal models of infectious arthritis in drug discovery: A focus on alphaviral disease

Current Drug Targets

Volumn 12, Issue 7, 2011, Pages 1024-1036

  Herrero, Lara ^a,b   Nelson, Michelle ^a   Bettadapura, Jayaram ^a,b   Gahan, Michelle E ^a   Mahalingam, Suresh ^a,b  

^a UNIVERSITY OF CANBERRA   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

Alphavirus; Animal models; Chemokines; Chikungunya virus; Cytokines; Macrophage; Ross River virus

Indexed keywords

3' FLURO 3' DEOXYADENOSINE; ANTIVIRUS AGENT; CHEMOKINE; CHIKUNGUNYA ALPHAVIRUS VACCINE; CHLOROQUINE; CYTOKINE; INDAZOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; QUININE; RECOMBINANT INTERFERON; RECOMBINANT VACCINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADAPTIVE IMMUNITY; ALPHA VIRUS; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; APOPTOSIS; ARTHRALGIA; ARTHRITIS; CELL PROLIFERATION; CELLULAR IMMUNITY; CHIKUNGUNYA ALPHAVIRUS; CHIKUNGUNYA ALPHAVIRUS INFECTION; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG TARGETING; EPIDEMIC; FEVER; FIBROBLAST; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; INFECTIOUS ARTHRITIS; MACROPHAGE; MAYARO ALPHAVIRUS; MONOCYTE; MYALGIA; NONHUMAN; O NYONG NYONG ALPHAVIRUS; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY; RASH; REVIEW; ROSS RIVER ALPHA VIRUS; SEMLIKI FOREST ALPHAVIRUS; SEMLIKI FOREST ALPHAVIRUS INFECTION; SINDBIS VIRUS; SINDBIS VIRUS INFECTION; VIRAL CLEARANCE; VIRAL TROPISM; VIREMIA; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS PATHOGENESIS; VIRUS REPLICATION;

EID: 79958175043     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011795677836     Document Type: Review

References (131)

1. Suhrbier A, Mahalingam S. The immunobiology of viral arthritides. Pharmacol Ther 2009; 124: 301-8.
2. Johnston RE, Peters CJ. Alphaviruses. 3rd ed. Fields BN, Knipe DM, Howley PM, eds. Philadelphia, PA: Lippincott-Raven Publishers 1996.
3. Lanciotti RS, Ludwig ML, Rwaguma EB, et al. Emergence of epidemic O'nyong-nyong fever in Uganda after a 35-year absence: genetic characterization of the virus. Virology 1998; 252(1): 258-68.
4. Posey DL, O'Rourke T, Roehrig JT, Lanciotti RS, Weinberg M, Maloney S. O'Nyong-nyong fever in West Africa. Am J Trop Med Hyg 2005; 73(1): 32.
5. Williams MC, Woodall JP, Corbet PS, Gillett JD. O'nyong-nyong Fever: an epidemic virus disease in East Africa. 8. Virus isolations from Anopheles mosquitoes. Trans R Soc Trop Med Hyg 1965; 59: 300-6.
6. Harley D, Sleigh A, Ritchie S. Ross River virus transmission, infection, and disease: a cross-disciplinary review. Clin Microbiol Rev 2001; 14(4): 909-32.
7. Azevedo RS, Silva EV, Carvalho VL, et al. Mayaro fever virus, Brazilian Amazon. Emerg Infect Dis 2009; 15: 1830-2.
8. Pinheiro FP, Freitas RB, Travassos da Rosa JF, Gabbay YB, Mello WA, LeDuc JW. An outbreak of Mayaro virus disease in Belterra, Brazil. I. Clinical and virological findings. Am J Trop Med Hyg 1981; 30(3): 674-81.
9. Josseran L, Paquet C, Zehgnoun A, et al. Chikungunya disease outbreak, Reunion Island. Emerg Infect Dis 2006; 12: 1994-5.
10. Kalantri SP, Joshi R, Riley LW. Chikungunya epidemic: an Indian perspective. Natl Med J India 2006; 19: 315-22.
11. Yergolkar PN, Tandale BV, Arankalle VA, et al. Chikungunya outbreaks caused by African genotype, India. Emerg Infect Dis 2006; 12: 1580-3.
12. Thavara U, Tawatsin A, Pengsakul T, et al. Outbreak of chikungunya fever in Thailand and virus detection in field population of vector mosquitoes, Aedes aegypti (L.) and Aedes albopictus Skuse (Diptera: Culicidae). Southeast Asian J Trop Med Public Health 2009; 40(5): 951-62.
13. Theamboonlers A, Rianthavorn P, Praianantathavorn K, Wuttirattanakowit N, Poovorawan Y. Clinical and molecular characterization of chikungunya virus in South Thailand. Jpn J Infect Dis 2009; 62(4): 303-5.
14. Lewthwaite P, Vasanthapuram R, Osborne JC, et al. Chikungunya virus and central nervous system infections in children, India. Emerg Infect Dis 2009; 15(2): 329-31.
15. Taylor RM, Hurlbut HS, Work TH, Kingston JR, Frothingham TE. Sindbis virus: a newly recognized arthropod transmitted virus. Am J Trop Med Hyg 1955; 4(5): 844-62.
16. Ryman KD, Klimstra WB. Host responses to alphavirus infection. Immunol Rev 2008; 225: 27-45.
17. Johnson RT. Virus invasion of the central nervous system: a study of sindbis virus infection in the mouse using fluorescent antibody. Am J Pathol 1965; 46: 929-43.
18. Klimstra WB, Ryman KD, Bernard KA, Nguyen KB, Biron CA, Johnston RE. Infection of neonatal mice with sindbis virus results in a systemic inflammatory response syndrome. J Virol 1999; 73(12): 10387-98.
19. Kurkela S, Manni T, Vaheri A, Vapalahti O. Causative agent of Pogosta disease isolated from blood and skin lesions. Emerg Infect Dis 2004; 10(5): 889-94.
20. Kurkela S, Manni T, Myllynen J, Vaheri A, Vapalahti O. Clinical and laboratory manifestations of Sindbis virus infection: prospective study, Finland, 2002-2003. J Infect Dis 2005; 191(11): 1820-9.
21. Trgovcich J, Aronson JF, Johnston RE. Fatal Sindbis virus infection of neonatal mice in the absence of encephalitis. Virology 1996; 224(1): 73-83.
22. Trgovcich J, Ryman K, Extrom P, Eldridge JC, Aronson JF, Johnston RE. Sindbis virus infection of neonatal mice results in a severe stress response. Virology 1997; 227(1): 234-8.
23. Fazakerley JK, Pathak S, Scallan M, Amor S, Dyson H. Replication of the A7(74) strain of Semliki Forest virus is restricted in neurons. Virology 1993; 195(2): 627-37.
24. Pusztai R, Gould EA, Smith H. Infection patterns in mice of an avirulent and virulent strain of Semliki Forest virus. Br J Exp Pathol 1971; 52(6): 669-77.
25. Atkins GJ, Sheahan BJ. Semliki forest virus neurovirulence mutants have altered cytopathogenicity for central nervous system cells. Infect Immun 1982; 36(1): 333-41.
26. Gates MC, Sheahan BJ, Atkins GJ. The pathogenicity of the M9 mutant of Semliki Forest virus in immune-compromised mice. J Gen Virol 1984; 65 (Pt 1): 73-80.
27. Amor S, Scallan MF, Morris MM, Dyson H, Fazakerley JK. Role of immune responses in protection and pathogenesis during Semliki Forest virus encephalitis. J Gen Virol 1996; 77 (Pt 2): 281-91.
28. Lidbury BA, Simeonovic C, Maxwell GE, Marshall ID, Hapel AJ. Macrophage-induced muscle pathology results in morbidity and mortality for Ross River virus-infected mice. J Infect Dis 2000; 181(1): 27-34.
29. Lidbury BA, Rulli NE, Suhrbier A, et al. Macrophage-derived proinflammatory factors contribute to the development of arthritis and myositis after infection with an arthrogenic alphavirus. J Infect Dis 2008; 197(11): 1585-93.
30. Morrison TE, Fraser RJ, Smith PN, Mahalingam S, Heise MT. Complement contributes to inflammatory tissue destruction in a mouse model of Ross River virus-induced disease. J Virol 2007; 81(10): 5132-43.
31. Morrison TE, Whitmore AC, Shabman RS, Lidbury BA, Mahalingam S, Heise MT. Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis. J Virol 2006; 80(2): 737-49.
32. Couderc T, Chretien F, Schilte C, et al. A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog 2008; 4(2): e29.
33. Ziegler SA, Lu L, da Rosa AP, Xiao SY, Tesh RB. An animal model for studying the pathogenesis of chikungunya virus infection. Am J Trop Med Hyg 2008; 79(1): 133-9.
34. Gardner J, Anraku I, Le TT, et al. Chikungunya Virus Arthritis in Adult Wild-Type Mice. J Virol 2010; 84(16): 8021-32.
35. Kobiler D, Rice CM, Brodie C, et al. A single nucleotide change in the 5' noncoding region of Sindbis virus confers neurovirulence in rats. J Virol 1999; 73(12): 10440-6.
36. Atkins GJ, Sheahan BJ, Mooney DA. Pathogenicity of Semliki Forest virus for the rat central nervous system and primary rat neural cell cultures: possible implications for the pathogenesis of multiple sclerosis. Neuropathol Appl Neurobiol 1990; 16(1): 57-68.
37. Zlotnik I, Harris WJ. The changes in cell organelles of neurons in the brains of adult mice and hamsters during Semliki Forest virus and louping ill encephalitis. Br J Exp Pathol 1970; 51(1): 37-42.
38. Bradish CJ, Allner K, Maber HB. The virulence of original and derived strains of Semliki forest virus for mice, guinea-pigs and rabbits. J Gen Virol 1971; 12(2): 141-60.
39. Bradish CJ, Allner K, Maber HB. Infection, interaction and the expression of virulence by defined strains of Semliki forest virus. J Gen Virol 1972; 16(3): 359-72.
40. Whitehead RH. Experimental infection of vertebrates with Ross River and Sindbis viruses, two group A arboviruses isolated in Australia. Aust J Exp Biol Med Sci 1969; 47(1): 11-5.
41. McIntosh BM, Paterson HE, Donaldson JM, Sousa J. Chikungunya virus: virus susceptibility and transmission studies with some vertebrates and mosquitoes. S Afr J Med Sci 1963; 28: 45-52.
42. Binn LN, Harrison VR, Randall R. Patterns of viremia and antibody observed in rhesus monkeys inoculated with chikungunya and other serologically related group A arboviruses. Am J Trop Med Hyg 1967; 16(6): 782-5.
43. Paul SD, Singh KR. Experimental infection of Macaca radiata with Chikungunya virus and transmission of virus by mosquitoes. Indian J Med Res 1968; 56(6): 802-11.
44. Labadie K, Larcher T, Joubert C, et al. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J Clin Invest 2010; 120(3): 894-906.
45. Hoarau JJ, Jaffar Bandjee MC, Trotot PK, et al. Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol 2010; 184(10): 5914-27.
46. Couderc T, Lecuit M. Focus on Chikungunya pathophysiology in human and animal models. Microbes Infect 2009; 11: 1197-205.
47. Burdeinick-Kerr R, Govindarajan D, Griffin DE. Noncytolytic clearance of sindbis virus infection from neurons by gamma interferon is dependent on Jak/STAT signaling. J Virol 2009; 83(8): 3429-35.
48. Levine B, Griffin DE. Molecular analysis of neurovirulent strains of Sindbis virus that evolve during persistent infection of scid mice. J Virol 1993; 67(11): 6872-5.
49. Levine B, Griffin DE. Persistence of viral RNA in mouse brains after recovery from acute alphavirus encephalitis. J Virol 1992; 66(11): 6429-35.
50. Levine B, Hardwick JM, Trapp BD, Crawford TO, Bollinger RC, Griffin DE. Antibody-mediated clearance of alphavirus infection from neurons. Science 1991; 254(5033): 856-60.
51. Morrison TE, Simmons JD, Heise MT. Complement receptor 3 promotes severe ross river virus-induced disease. J Virol 2008; 82(22): 11263-72.
52. Mateo L, La Linn M, McColl SR, Cross S, Gardner J, Suhrbier A. An arthrogenic alphavirus induces monocyte chemoattractant protein-1 and interleukin-8. Intervirology 2000; 43(1): 55-60.
53. Rulli NE, Guglielmotti A, Mangano G, et al. Amelioration of alphavirus-induced arthritis and myositis in a mouse model by treatment with bindarit, an inhibitor of monocyte chemotactic proteins. Arthritis Rheum 2009; 60(8): 2513-23.
54. Ng LF, Chow A, Sun YJ, et al. IL-1beta, IL-6, and RANTES as biomarkers of Chikungunya severity. PLoS One 2009; 4(1): e4261.
55. Mylonas AD, Brown AM, Carthew TL, et al. Natural history of Ross River virus-induced epidemic polyarthritis. Med J Aust 2002; 177(7): 356-60.
56. Oosterlaken TAM, Harmsen M, Jhagjhoor-Singh SS, Ekstijn GL, Kraaijeveld CA, Snippe H. A protective monoclonal anti-idiotypic vaccine to lethal Semliki Forest virus infection in BALB/c mice. J Virol 1991; 65(1): 98-102.
57. Kraaijeveld CA, Oosterlaken TA, Snijders A, Benaissa-Trouw BJ, Ekstijn GL, Snippe H. A vaccine against Semliki Forest virus consisting of a monoclonal anti-idiotypic antibody cross-linked to a protein which contains virus-specific T-helper cell epitopes. Antiviral Research 1992; 19(4): 275-84.
58. Snijders A, Benaissa-Trouw BJ, Snippe H, Kraaijeveld CA. Immunogenicity and vaccine efficacy of synthetic peptides containing Semliki Forest virus B and T cell epitopes. J Gen Virol 1992; 73(9): 2267-72.
59. Balcarova J, Helenius A, Simons K. Antibody response to spike protein vaccines prepared from Semliki Forest virus. J Gen Virol 1981; 53: 85-92.
60. Grosfeld H, Velan B, Leitner M, et al. Semliki Forest virus E2 envelope epitopes induce a nonneutralizing humoral response which protects mice against lethal challenge. J Virol 1989; 63(8): 3416-22.
61. Aaskov J, Williams L, Yu S. A candidate Ross River virus vaccine: preclinical evaluation. Vaccine 1997; 15(12-13): 1396-404.
62. Kistner O, Barrett N, Brühmann A, et al. The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans. Vaccine 2007; 25(25): 4845-52.
63. Muthumani K, Lankaraman KM, Laddy DJ, et al. Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine 2008; 26(40): 5128-34.
64. Tiwari M, Parida M, Santhosh SR, Khan M, Dash PK, Rao PV. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 2009; 27(18): 2513-22.
65. Harrison VR, Eckels KH, Bartelloni PJ, Hampton C. Production and evaluation of a formalin-killed chikungunya vaccine. J Immunol 1971; 107: 643-7.
66. Levitt NH, Ramsburg HH, Hasty SE, Repik PM, Cole FEJ, Lupton HW. Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine 1986; 4: 157-62.
67. McClain DJ, Pittman PR, Ramsburg HH, et al. Immunologic interference from sequential administration of live attenuated alphavirus vaccines. J Infect Dis 1998; 177: 634-41.
68. Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg 2000; 62(6): 681-5.
69. Akahata W, Yang ZY, Andersen H, et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med 2010; 16(3): 334-8.
70. Paessler S, Ni H, Petrakova O, et al. Replication and clearance of Venezuelan equine encephalitis virus from the brains of animals vaccinated with chimeric SIN/VEE viruses. J Virol 2006; 80(6): 2784-96.
71. Wang E, Volkova E, Adams AP, et al. Chimeric alphavirus vaccine candidates for chikungunya. Vaccine 2008; 26(39): 5030-9.
72. Phillpotts R. Immunity to airborne challenge with Venezuelan equine encephalitis virus develops rapidly after immunisation with the attenuated vaccine strain TC-83. Vaccine 1999; 17(19): 2429-35.
73. Stanley J, Cooper S, Griffin D. Monoclonal antibody cure and prophylaxis of lethal Sindbis virus encephalitis in mice. J Virol 1986; 58(1): 107-15.
74. Couderc T, Khandoudi N, Grandadam M, et al. Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis 2009; 200: 516-23.
75. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147(927): 258-67.
76. Muller U, Steinhoff U, Reis LF, et al. Functional role of type I and type II interferons in antiviral defense. Science 1994; 264(5167): 1918-21.
77. Hwang SY, Hertzog PJ, Holland KA, et al. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. Proc Natl Acad Sci U S A 1995; 92(24): 11284-8.
78. Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Trends Microbiol 2000; 8(9): 410-8.
79. Cruz CC, Suthar MS, Montgomery SA, et al. Modulation of type I IFN induction by a virulence determinant within the alphavirus nsP1 protein. Virology 2010; 399: 1-10.
80. Heise MT, Simpson DA, Johnston RE. A single amino acid change in nsP1 attenuates neurovirulence of the Sindbis-group alphavirus S.A. AR86. J Virol 2000; 74(9): 4207-13.
81. Rikkonen M. Functional significance of the nuclear-targeting and NTP-binding motifs of Semliki Forest virus nonstructural protein nsP2. Virology 1996; 218: 352-36.
82. Fazakerley JK, Boyd A, Mikkola ML, Kaariainen L. A single amino acid change in the nuclear localization sequence of the nsP2 protein affects the neurovirulence of Semliki Forest virus. J Virol 2002; 76: 392-6.
83. Breakwell L, Dosenovic P, Karlsson Hedestam GB, et al. Semliki Forest virus nonstructural protein 2 is involved in suppression of the type I interferon response. J Virol 2007; 81(16): 8677-84.
84. Mahalingam S, Lidbury BA. Suppression of lipopolysaccharideinduced antiviral transcription factor (STAT-1 and NF-kappa B) complexes by antibody-dependent enhancement of macrophage infection by Ross River virus. Proc Natl Acad Sci U S A 2002; 99(21): 13819-24.
85. Ryman KD, Klimstra WB, Nguyen KB, Biron CA, Johnston RE. Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism. J Virol 2000; 74(7): 3366-78.
86. Tomkins PT, Ward GA, Morris AG. Role of interferon-gamma in T-cell responses to Semliki Forest virus-infected murine brain cells. Immunology 1988; 63(3): 355-62.
87. Shabman RS, Morrison TE, Moore C, et al. Differential induction of type I interferon responses in myeloid dendritic cells by mosquito and mammalian-cell-derived alphaviruses. J Virol 2007; 81(1): 237-47.
88. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
89. Takeuchi O, Akira S. MDA5/RIG-I and virus recognition. Curr Opin Immunol 2008; 20(1): 17-22.
90. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001; 13(2): 85-94.
91. Uematsu S, Akira S. Toll-like receptors and Type I interferons. J Biol Chem 2007; 282(21): 15319-23.
92. O'Neill LA. Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr Opin Pharmacol 2003; 3(4): 396-403.
93. O'Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of Tolllike receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 2009; 61(2): 177-97.
94. Morris MM, Dyson H, Baker D, Harbige LS, Fazakerley JK, Amor S. Characterization of the cellular and cytokine response in the central nervous system following Semliki Forest virus infection. J Neuroimmunol 1997; 74(1-2): 185-97.
95. Trgovcich J, Aronson JF, Eldridge JC, Johnston RE. TNFalpha, interferon, and stress response induction as a function of agerelated susceptibility to fatal Sindbis virus infection of mice. Virology 1999; 263(2): 339-48.
96. Gifford GE, Duckworth DH. Introduction to TNF and related lymphokines. Biotherapy 1991; 3(2): 103-11.
97. Rahman MM, McFadden G. Modulation of tumor necrosis factor by microbial pathogens. PLoS Pathog 2006; 2(2): e4.
98. Meador R, Hsia E, Kitumnuaypong T, Schumacher HR. TNF involvement and anti-TNF therapy of reactive and unclassified arthritis. Clin Exp Rheumatol 2002; 20(6 Suppl 28): S130-4.
99. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003; 3(10): 791-800.
100. Santos LL, Morand EF. The role of macrophage migration inhibitory factor in the inflammatory immune response and rheumatoid arthritis. Wien Med Wochenschr 2006; 156(1-2): 11-8.
101. Santos LL, Morand EF. Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis. Clin Chim Acta 2009; 399(1-2): 1-7.
102. Murray PJ. Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr Opin Pharmacol 2006; 6(4): 379-86.
103. Grieder FB, Davis BK, Zhou XD, Chen SJ, Finkelman FD, Gause WC. Kinetics of cytokine expression and regulation of host protection following infection with molecularly cloned Venezuelan equine encephalitis virus. Virology 1997; 233(2): 302-12.
104. Rowell JF, Griffin DE. The inflammatory response to nonfatal Sindbis virus infection of the nervous system is more severe in SJL than in BALB/c mice and is associated with low levels of IL-4 mRNA and high levels of IL-10-producing CD4+ T cells. J Immunol 1999; 162(3): 1624-32.
105. Wesselingh SL, Levine B, Fox RJ, Choi S, Griffin DE. Intracerebral cytokine mRNA expression during fatal and nonfatal alphavirus encephalitis suggests a predominant type 2 T cell response. J Immunol 1994; 152(3): 1289-97.
106. Roers A, Siewe L, Strittmatter E, et al. T cell-specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. J Exp Med 2004; 200(10): 1289-97.
107. Ejrnaes M, von Herrath MG. Cure of chronic viral infection by neutralizing antibody treatment. Autoimmun Rev 2007; 6(5): 267-71.
108. Gong JH, Yan R, Waterfield JD, Clark-Lewis I. Post-onset inhibition of murine arthritis using combined chemokine antagonist therapy. Rheumatology (Oxford) 2004; 43(1): 39-42.
109. Maurer M, von Stebut E. Macrophage inflammatory protein-1. Int J Biochem Cell Biol 2004; 36(10): 1882-6.
110. Horuk R. Development and evaluation of pharmacological agents targeting chemokine receptors. Methods 2003; 29(4): 369-75.
111. Zoja C, Corna D, Benedetti G, et al. Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int 1998; 53(3): 726-34.
112. Guglielmotti A, D'Onofrio E, Coletta I, Aquilini L, Milanese C, Pinza M. Amelioration of rat adjuvant arthritis by therapeutic treatment with bindarit, an inhibitor of MCP-1 and TNF-alpha production. Inflamm Res 2002; 51(5): 252-8.
113. Guglielmotti A, Aquilini L, D'Onofrio E, Rosignoli MT, Milanese C, Pinza M. Bindarit prolongs survival and reduces renal damage in NZB/W lupus mice. Clin Exp Rheumatol 1998; 16(2): 149-54.
114. Bhatia M, Ramnath RD, Chevali L, Guglielmotti A. Treatment with bindarit, a blocker of MCP-1 synthesis, protects mice against acute pancreatitis. Am J Physiol Gastrointest Liver Physiol 2005; 288(6): G1259-65.
115. Mirolo M, Fabbri M, Sironi M, et al. Impact of the antiinflammatory agent bindarit on the chemokinome: selective inhibition of the monocyte chemotactic proteins. Eur Cytokine Netw 2008; 19(3): 119-22.
116. Ben-Nathan D, Maestroni GJ, Lustig S, Conti A. Protective effects of melatonin in mice infected with encephalitis viruses. Arch Virol 1995; 140(2): 223-30.
117. Pinto AJ, Morahan PS, Brinton M, Stewart D, Gavin E. Comparative therapeutic efficacy of recombinant interferons-alpha,-beta, and-gamma against alphatogavirus, bunyavirus, flavivirus, and herpesvirus infections. J Interferon Res 1990; 10(3): 293-8.
118. Smee DF, Alaghamandan HA, Kini GD, Robins RK. Antiviral activity and mode of action of ribavirin 5'-sulfamate against Semliki Forest virus. Antiviral Res 1988; 10(6): 253-62.
119. Pinto AJ, Morahan PS, Brinton MA. Comparative study of various immunomodulators for macrophage and natural killer cell activation and antiviral efficacy against exotic RNA viruses. Int J Immunopharmacol 1988; 10(3): 197-209.
120. Sidwell RW, Smee DF. Viruses of the Bunya-and Togaviridae families: potential as bioterrorism agents and means of control. Antiviral Res 2003; 57(1-2): 101-11.
121. Li Y, Wang L, Li S, et al. Seco-pregnane steroids target the subgenomic RNA of alphavirus-like RNA viruses. Proc Natl Acad Sci U S A 2007; 104(19): 8083-8.
122. Bai H, Li W, Asada Y, Satou T, Wang Y, Koike K. Twelve pregnane glycosides from Cynanchum atratum. Steroids 2009; 74(2): 198-207.
123. Cassell S, Edwards J, Brown DT. Effects of lysosomotropic weak bases on infection of BHK-21 cells by Sindbis virus. J Virol 1984; 52(3): 857-64.
124. Coombs K, Mann E, Edwards J, Brown DT. Effects of chloroquine and cytochalasin B on the infection of cells by Sindbis virus and vesicular stomatitis virus. J Virol 1981; 37(3): 1060-5.
125. Helenius A, Marsh M, White J. Inhibition of Semliki forest virus penetration by lysosomotropic weak bases. J Gen Virol 1982; 58 Pt 1: 47-61.
126. Maheswari RK, Srikantan V, Bhartiya D. Chloroquine enhances replication of Semliki Forest Virus and Encephalomyocarditis virus in Mice. J Virol 1991; 65: 992-5.
127. De Lamballerie XD, Boisson V, Reynier J, et al. On Chikungunya acute infection and chloroquine treatment. Vector Borne and Zoonotic Dis 2008; 8: 837-9.
128. Gould EA, Coutard B, Malet H, et al. Understanding the alphaviruses: recent research on important emerging pathogens and progress towards their control. Antiviral Res 2010; 87(2): 111-24.
129. Van Aerschot A, Herdewijn P, Janssen G, Cools M, De Clercq E. Synthesis and antiviral activity evaluation of 3'-fluoro-3'-deoxyribonucleosides: broad-spectrum antiviral activity of 3'-fluoro-3'-deoxyadenosine. Antiviral Res 1989; 12(3): 133-50.
130. Pohjala L, Barai V, Azhayev A, Lapinjoki S, Ahola T. A luciferase-based screening method for inhibitors of alphavirus replication applied to nucleoside analogues. Antiviral Res 2008; 78(3): 215-22.
131. Dash PK, Tiwari M, Santhosh SR, Parida M, Lakshmana Rao PV. RNA interference mediated inhibition of Chikungunya virus replication in mammalian cells. Biochem Biophys Res Commun 2008; 376(4): 718-22.